Comparison of the replication and neutralization of different SARS-CoV-2 Omicron subvariants in vitro.
Omicron
SARS-CoV-2
cross-neutralize
replication
Journal
Animal models and experimental medicine
ISSN: 2576-2095
Titre abrégé: Animal Model Exp Med
Pays: United States
ID NLM: 101726292
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
26
10
2022
accepted:
11
12
2022
pubmed:
23
2
2023
medline:
8
3
2023
entrez:
22
2
2023
Statut:
ppublish
Résumé
New Omicron subvariants are emerging rapidly from BA.1 to BA.4 and BA.5. Their pathogenicity has changed from that of wild-type (WH-09) and Omicron variants have over time become globally dominant. The spike proteins of BA.4 and BA.5 that serve as the target for vaccine-induced neutralizing antibodies have also changed compared to the previous subvariants, which is likely to cause immune escape and the reduction of the protective effect of the vaccine. Our study addresses the above issues and provides a basis for formulating relevant prevention and control strategies. We collected cellular supernatant and cell lysates and measured the viral titers, viral RNA loads, and E subgenomic RNA (E sgRNA) loads in different Omicron subvariants grown in Vero E6 cells, using WH-09 and Delta variants as a reference. Additionally, we evaluated the in vitro neutralizing activity of different Omicron subvariants and compared it to the WH-09 and Delta variants using macaque sera with different types of immunity. As the SARS-CoV-2 evolved into Omicron BA.1, the replication ability in vitro began to decrease. Then with the emergence of new subvariants, the replication ability gradually recovered and became stable in the BA.4 and BA.5 subvariants. In WH-09-inactivated vaccine sera, geometric mean titers of neutralization antibodies against different Omicron subvariants declined by 3.7~15.4-fold compared to those against WH-09. In Delta-inactivated vaccine sera, geometric mean titers of neutralization antibodies against Omicron subvariants declined by 3.1~7.4-fold compared to those against Delta. According to the findings of this research, the replication efficiency of all Omicron subvariants declined compared with WH-09 and Delta variants, and was lower in BA.1 than in other Omicron subvariants. After two doses of inactivated (WH-09 or Delta) vaccine, cross-neutralizing activities against various Omicron subvariants were seen despite a decline in neutralizing titers.
Sections du résumé
BACKGROUND
New Omicron subvariants are emerging rapidly from BA.1 to BA.4 and BA.5. Their pathogenicity has changed from that of wild-type (WH-09) and Omicron variants have over time become globally dominant. The spike proteins of BA.4 and BA.5 that serve as the target for vaccine-induced neutralizing antibodies have also changed compared to the previous subvariants, which is likely to cause immune escape and the reduction of the protective effect of the vaccine. Our study addresses the above issues and provides a basis for formulating relevant prevention and control strategies.
METHODS
We collected cellular supernatant and cell lysates and measured the viral titers, viral RNA loads, and E subgenomic RNA (E sgRNA) loads in different Omicron subvariants grown in Vero E6 cells, using WH-09 and Delta variants as a reference. Additionally, we evaluated the in vitro neutralizing activity of different Omicron subvariants and compared it to the WH-09 and Delta variants using macaque sera with different types of immunity.
RESULTS
As the SARS-CoV-2 evolved into Omicron BA.1, the replication ability in vitro began to decrease. Then with the emergence of new subvariants, the replication ability gradually recovered and became stable in the BA.4 and BA.5 subvariants. In WH-09-inactivated vaccine sera, geometric mean titers of neutralization antibodies against different Omicron subvariants declined by 3.7~15.4-fold compared to those against WH-09. In Delta-inactivated vaccine sera, geometric mean titers of neutralization antibodies against Omicron subvariants declined by 3.1~7.4-fold compared to those against Delta.
CONCLUSION
According to the findings of this research, the replication efficiency of all Omicron subvariants declined compared with WH-09 and Delta variants, and was lower in BA.1 than in other Omicron subvariants. After two doses of inactivated (WH-09 or Delta) vaccine, cross-neutralizing activities against various Omicron subvariants were seen despite a decline in neutralizing titers.
Identifiants
pubmed: 36808904
doi: 10.1002/ame2.12302
pmc: PMC9986223
doi:
Substances chimiques
Antibodies, Neutralizing
0
Subgenomic RNA
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
51-56Informations de copyright
© 2023 The Authors. Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.
Références
Animal Model Exp Med. 2023 Feb;6(1):51-56
pubmed: 36808904
Cell. 2022 Jul 7;185(14):2422-2433.e13
pubmed: 35772405
Cell. 2021 Aug 5;184(16):4203-4219.e32
pubmed: 34242577
Cell. 2022 Jun 9;185(12):2103-2115.e19
pubmed: 35568035
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Nature. 2022 Jun;606(7916):848-849
pubmed: 35750920
Nature. 2020 Jul;583(7818):830-833
pubmed: 32380511
Cell Host Microbe. 2022 Sep 14;30(9):1231-1241.e6
pubmed: 35921836
Nature. 2022 Aug;608(7923):603-608
pubmed: 35790190
Nature. 2022 Aug;608(7923):593-602
pubmed: 35714668
Signal Transduct Target Ther. 2022 Mar 9;7(1):76
pubmed: 35264568
Signal Transduct Target Ther. 2022 Jul 19;7(1):241
pubmed: 35853878
J Gen Virol. 2020 Sep;101(9):925-940
pubmed: 32568027
China CDC Wkly. 2022 Apr 8;4(14):293-297
pubmed: 35433093
Emerg Microbes Infect. 2022 Dec;11(1):1828-1832
pubmed: 35792746
Virol J. 2022 Apr 26;19(1):76
pubmed: 35473640
Cell Host Microbe. 2021 Jul 14;29(7):1124-1136.e11
pubmed: 34171266
Cell Mol Life Sci. 2021 Apr;78(7):3565-3576
pubmed: 33449149
Clin Microbiol Infect. 2022 Feb;28(2):202-221
pubmed: 34715347